drugset

drugset / Trial / NCT00105092

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

NCT00105092 ↗

Phase 2 Completed 50 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.

Timeline

Start: 2005-03
Primary completion: —
Completion: 2007-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	enzastaurin	Small molecule	—	Oral

Indications